Standard BioTools Inc.

NASDAQ:LAB

Medical - Devices

Healthcare
$0.57 +3.38%

+$0.03 today

Market cap
$225.03M
Beta
1.38
P/E (TTM)
-3.5
EPS (TTM)
-$0.24
52W Low $0.79High $1.72

Volume 0.70M

Average 2.91M

LAB Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Standard BioTools Inc.NASDAQ: LAB

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $18.61M fell 37.6% year over year, behind the -22.9% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 23.7% from the prior quarter. Over 3 fiscal years it compounded at +2.4% a year.

Context

  • Selling, general & admin amounted to 128.7% of revenue in FY2025, up 39.0 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 1 analysts of $79.37M (-27.8%) for the fiscal year ending Dec 2026, a step up from the -29.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$18.61M-23.7% QoQ
Last fiscal yearDec 2025
$109.86M-29.8% YoY
LTMMar 2026
$97.69M-22.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-37.6%-28.8%+8.8 pp
1 year-29.8%-27.8%+2.1 pp
3-year CAGR+2.4%-9.1%-11.5 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
109.86M USD
Year-over-year change
-29.8%
4-year CAGR
+2.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How LAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -22.9% is the lowest of 11, against a peer median of +5.8%.
  • Selling, general & admin amounts to 113.3% of revenue for LAB, versus a peer median of 55.4%.
LAB Competitors
Selling, General & Admin for LAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYSo-Young International Inc.LTM Mar 2026CN¥910.25M CNY+17.1%+4.4%55.2%
BVSBioventus Inc.LTM Mar 2026$317.73M USD-6.0%-2.1%55.1%
AVNSAvanos Medical, Inc.LTM Mar 2026$290.1M USD-3.4%-12.3%40.5%
TMCITreace Medical Concepts, Inc.LTM Mar 2026$200.66M USD+0.0%+14.0%96.8%
KIDSOrthoPediatrics Corp.LTM Mar 2026$195.2M USD+11.5%+22.8%80.2%
VREXVarex Imaging CorporationLTM Apr 2026$135.6M USD-0.5%+4.1%15.8%
CBLLCeriBell, Inc.LTM Mar 2026$127.27M USD+37.1%+32.7%133.9%
CTKBCytek Biosciences, Inc.LTM Mar 2026$113.08M USD+20.7%+16.9%55.4%
LABStandard BioTools Inc.LTM Mar 2026$97.69M USD-22.9%+2.4%113.3%
ADCTADC Therapeutics S.A.LTM Mar 2026$82.03M USD+32.5%—103.6%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$52.28M USD-5.2%+10.5%—
Peer median (excluding LAB) —+5.8%+10.5%55.4%

Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue130.58M97.95M106.34M174.43M85.33M
Cost of Revenue61.21M60.9M55.89M90.17M42.79M
Gross Profit69.37M37.05M50.45M84.26M42.54M
Gross Margin53.1%37.8%47.4%48.3%49.9%
Research & Development37.94M37.38M25.95M62.41M25.99M
Selling, General & Admin98.89M102.29M87.54M156.61M109.86M
Operating Expenses136.83M153.26M127.05M259.5M135.85M
Depreciation & Amortization15.57M15.03M15.18M16.86M6.98M
EBITDA(44.27M)(173.57M)(54.46M)(118.14M)(89.69M)
EBITDA Margin-33.9%-177.2%-51.2%-67.7%-105.1%
Operating Income(67.46M)(116.21M)(76.6M)(175.24M)(93.31M)
Operating Margin-51.7%-118.6%-72.0%-100.5%-109.3%
Interest Income02.23M5.57M20.2M9.18M
Interest Expense3.82M4.33M4.57M3.32M26K
Other Income / Expenses3.8M(76.72M)2.4M36.92M(3.4M)
Income Before Tax(63.66M)(192.93M)(74.2M)(138.31M)(96.7M)
Pre-Tax Margin-48.8%-197.0%-69.8%-79.3%-113.3%
Income Tax Expense(4.42M)(2.83M)452K573K(37.88M)
Net Income(59.24M)(190.1M)(74.66M)(138.89M)(74.9M)
Net Margin-45.4%-194.1%-70.2%-79.6%-87.8%
EPS (Basic)(0.78)(2.43)(0.94)(0.52)(0.20)
EPS (Diluted)(0.78)(2.43)(0.94)(0.52)(0.20)
Weighted Avg Shares75.79M78.31M79.16M352.67M381.62M
Weighted Avg Shares (Diluted)75.79M78.31M79.16M352.67M381.62M

Standard BioTools Inc.

NASDAQ:LAB

Intrinsic Alpha fair value

Locked

Current Price

$0.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.